Redeye updates its estimates following Sleep Cycle’s Q2’22 report.
Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and an...
As the Q2 report and the trading update for Q3 did not contain any surprises, we leave our 2022-24 e...
Ferronordic's report was a mixed bag. We calculate that group sales declined 15% organically, while ...
Strong core business only offset by trading income Hunt for new corporate customers off to good star...
Low demand for B2C products weighs on Q2 Baux outsourced and royalty model implemented Working capit...
Bolaget minskar både omsättning och rörelseresultat under kvartalet men rapporten bjuder på några lj...
Redeye comments on Coala Life’s Q2’22 report and the acquisition of Vitrics.
10% organisk tillväxt Intäkter i Q2'22 uppgick till 192,5 mkr (171,5 mkr i Q2'21), vilket motsvarar ...
Q2-rapport OncoZenge presenterade under gårdagen sin rapport för det andra kvartalet.
Utvecklingen har varit stabil i samtliga regioner och fokus ligger på att återfå tidigare momentum o...
19% revenue growth y-o-y, gross profit 21% above Reiterates 2022 target, but sees increased uncertai...
Decent NWT ramp-up in Q2, will accelerate in H2 Continued NWC build-up could cause some fears 13-8x ...
Redeye comments on Adverty’s Q2’22 report. Both sales and profitability came in below our expectatio...
Reassuring Q2 numbers and outlook We raise ‘23e-‘24e estimates Share is trading at 6x ’23e EV/EBITA ...
Adj. EBIT SEK 10.4m (+38% vs. ABGSCe 7.5m) Isolated Q2 figures imply 7-4% estimate upgrades 22x ’22e...
Raketech just released a somewhat soft Q2 report, and a decent start to Q3.
Marimekko delivered strong Q2 result, with net sales broadly in line with and EBIT beating our estim...
Conducting business in Russia becoming more difficult Evaluating a potential divestment 2-7x ’22e-’2...
Redeye lowers its forecast and base case valuation of Alelion following a Q2’22 report on the weak s...
